326 related articles for article (PubMed ID: 26715116)
21. Identification of the DEAD box RNA helicase DDX3 as a therapeutic target in colorectal cancer.
Heerma van Voss MR; Vesuna F; Trumpi K; Brilliant J; Berlinicke C; de Leng W; Kranenburg O; Offerhaus GJ; Bürger H; van der Wall E; van Diest PJ; Raman V
Oncotarget; 2015 Sep; 6(29):28312-26. PubMed ID: 26311743
[TBL] [Abstract][Full Text] [Related]
22. Blocking Wnt Secretion Reduces Growth of Hepatocellular Carcinoma Cell Lines Mostly Independent of β-Catenin Signaling.
Wang W; Xu L; Liu P; Jairam K; Yin Y; Chen K; Sprengers D; Peppelenbosch MP; Pan Q; Smits R
Neoplasia; 2016 Dec; 18(12):711-723. PubMed ID: 27851986
[TBL] [Abstract][Full Text] [Related]
23.
Yang F; Fang E; Mei H; Chen Y; Li H; Li D; Song H; Wang J; Hong M; Xiao W; Wang X; Huang K; Zheng L; Tong Q
Cancer Res; 2019 Feb; 79(3):557-571. PubMed ID: 30563889
[TBL] [Abstract][Full Text] [Related]
24. Targeting the Neurokinin-1 Receptor Compromises Canonical Wnt Signaling in Hepatoblastoma.
Ilmer M; Garnier A; Vykoukal J; Alt E; von Schweinitz D; Kappler R; Berger M
Mol Cancer Ther; 2015 Dec; 14(12):2712-21. PubMed ID: 26516161
[TBL] [Abstract][Full Text] [Related]
25. Inhibition of Wnt-2 and galectin-3 synergistically destabilizes beta-catenin and induces apoptosis in human colorectal cancer cells.
Shi Y; He B; Kuchenbecker KM; You L; Xu Z; Mikami I; Yagui-Beltran A; Clement G; Lin YC; Okamoto J; Bravo DT; Jablons DM
Int J Cancer; 2007 Sep; 121(6):1175-81. PubMed ID: 17534895
[TBL] [Abstract][Full Text] [Related]
26. Preclinical evaluation of destruxin B as a novel Wnt signaling target suppressing proliferation and metastasis of colorectal cancer using non-invasive bioluminescence imaging.
Yeh CT; Rao YK; Ye M; Wu WS; Chang TC; Wang LS; Wu CH; Wu AT; Tzeng YM
Toxicol Appl Pharmacol; 2012 May; 261(1):31-41. PubMed ID: 22465936
[TBL] [Abstract][Full Text] [Related]
27. Tbx3 is a downstream target of the Wnt/beta-catenin pathway and a critical mediator of beta-catenin survival functions in liver cancer.
Renard CA; Labalette C; Armengol C; Cougot D; Wei Y; Cairo S; Pineau P; Neuveut C; de Reyniès A; Dejean A; Perret C; Buendia MA
Cancer Res; 2007 Feb; 67(3):901-10. PubMed ID: 17283120
[TBL] [Abstract][Full Text] [Related]
28. Growth inhibition effect of β-catenin small interfering RNA-mediated gene silencing on human colon carcinoma HT-29 cells.
Xu WL; Wang Q; Du M; Zhao YH; Sun XR; Sun WG; Chen BQ
Cancer Biother Radiopharm; 2010 Oct; 25(5):529-37. PubMed ID: 20950152
[TBL] [Abstract][Full Text] [Related]
29. Overexpression of regenerating islet-derived 1 alpha and 3 alpha genes in human primary liver tumors with beta-catenin mutations.
Cavard C; Terris B; Grimber G; Christa L; Audard V; Radenen-Bussiere B; Simon MT; Renard CA; Buendia MA; Perret C
Oncogene; 2006 Jan; 25(4):599-608. PubMed ID: 16314847
[TBL] [Abstract][Full Text] [Related]
30. Inhibition of the Tcf/beta-catenin complex increases apoptosis and impairs adrenocortical tumor cell proliferation and adrenal steroidogenesis.
Leal LF; Bueno AC; Gomes DC; Abduch R; de Castro M; Antonini SR
Oncotarget; 2015 Dec; 6(40):43016-32. PubMed ID: 26515592
[TBL] [Abstract][Full Text] [Related]
31. In vitro RNA interference against beta-catenin inhibits the proliferation of pediatric hepatic tumors.
Sangkhathat S; Kusafuka T; Miao J; Yoneda A; Nara K; Yamamoto S; Kaneda Y; Fukuzawa M
Int J Oncol; 2006 Mar; 28(3):715-22. PubMed ID: 16465377
[TBL] [Abstract][Full Text] [Related]
32. Berberine acts as a natural inhibitor of Wnt/β-catenin signaling--identification of more active 13-arylalkyl derivatives.
Albring KF; Weidemüller J; Mittag S; Weiske J; Friedrich K; Geroni MC; Lombardi P; Huber O
Biofactors; 2013; 39(6):652-62. PubMed ID: 23982892
[TBL] [Abstract][Full Text] [Related]
33. HGF/c-Met related activation of β-catenin in hepatoblastoma.
Purcell R; Childs M; Maibach R; Miles C; Turner C; Zimmermann A; Sullivan M
J Exp Clin Cancer Res; 2011 Oct; 30(1):96. PubMed ID: 21992464
[TBL] [Abstract][Full Text] [Related]
34. SS18-SSX fusion protein-induced Wnt/β-catenin signaling is a therapeutic target in synovial sarcoma.
Trautmann M; Sievers E; Aretz S; Kindler D; Michels S; Friedrichs N; Renner M; Kirfel J; Steiner S; Huss S; Koch A; Penzel R; Larsson O; Kawai A; Tanaka S; Sonobe H; Waha A; Schirmacher P; Mechtersheimer G; Wardelmann E; Büttner R; Hartmann W
Oncogene; 2014 Oct; 33(42):5006-16. PubMed ID: 24166495
[TBL] [Abstract][Full Text] [Related]
35. Upregulated YAP promotes oncogenic CTNNB1 expression contributing to molecular pathology of hepatoblastoma.
Lu S; Jiang M; Chen Q; Luo X; Cao Z; Huang H; Zheng M; Du J
Pediatr Blood Cancer; 2022 Sep; 69(9):e29705. PubMed ID: 35404538
[TBL] [Abstract][Full Text] [Related]
36. TTK Inhibitors as a Targeted Therapy for
Zaman GJR; de Roos JADM; Libouban MAA; Prinsen MBW; de Man J; Buijsman RC; Uitdehaag JCM
Mol Cancer Ther; 2017 Nov; 16(11):2609-2617. PubMed ID: 28751540
[TBL] [Abstract][Full Text] [Related]
37. LKB1 signaling is activated in CTNNB1-mutated HCC and positively regulates β-catenin-dependent CTNNB1-mutated HCC.
Charawi S; Just PA; Savall M; Abitbol S; Traore M; Metzger N; Ravinger R; Cavard C; Terris B; Perret C
J Pathol; 2019 Apr; 247(4):435-443. PubMed ID: 30566242
[TBL] [Abstract][Full Text] [Related]
38. Mutant
Crippa S; Ancey PB; Vazquez J; Angelino P; Rougemont AL; Guettier C; Zoete V; Delorenzi M; Michielin O; Meylan E
EMBO Mol Med; 2017 Nov; 9(11):1589-1604. PubMed ID: 28923827
[TBL] [Abstract][Full Text] [Related]
39. Inhibition of β-catenin signalling promotes DNA damage elicited by benzo[a]pyrene in a model of human colon cancer cells via CYP1 deregulation.
Kabátková M; Zapletal O; Tylichová Z; Neča J; Machala M; Milcová A; Topinka J; Kozubík A; Vondráček J
Mutagenesis; 2015 Jul; 30(4):565-76. PubMed ID: 25805023
[TBL] [Abstract][Full Text] [Related]
40. β-catenin knockdown promotes NHERF1-mediated survival of colorectal cancer cells: implications for a double-targeted therapy.
Saponaro C; Sergio S; Coluccia A; De Luca M; La Regina G; Mologni L; Famiglini V; Naccarato V; Bonetti D; Gautier C; Gianni S; Vergara D; Salzet M; Fournier I; Bucci C; Silvestri R; Passerini CG; Maffia M; Coluccia AML
Oncogene; 2018 Jun; 37(24):3301-3316. PubMed ID: 29551770
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
